ESR1 and breast cancer: Recent studies using genome-wide CRISPR screens demonstrate that genes encoding the BAF complex—including ARID1A—mediate therapeutic response to ER antagonists; loss of ARID1A enhances proliferative capacity, rendering ER-positive breast cancer cell lines resistant to both tamoxifen and fulvestrant [39].